TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21149673

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/m2/dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide 40 mg/m2/dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide 55 mg/m2/dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide 70 mg/m2/dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide (general)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide (PK studies)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide (immunomodulatory studies)
Number of subjects: 49
Study: 21149764

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21150563

Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 157
Study: 21150709

Group type: EXPERIMENTAL
Intervention: Two-component mRNA-based tumor vaccine (free and protamine-complexed mRNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-component mRNA-based tumor vaccine
Number of subjects: 0
Study: 21150884

Group type: EXPERIMENTAL
Intervention: Minor allele of rs1656930
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs1656930 and rs9882205
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Ile164Thr genotype
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Common variant of ADIPOQ (minor allele of rs1656930)
Number of subjects: 3297
Study: 21155613

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 100 μg, administered once daily as a subcutaneous injection for 12 months
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 112
Study: 21155708

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1012
Study: 21156020

Group type: EXPERIMENTAL
Intervention: AMG 102 at 10 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: AMG 102 at 20 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: AMG 102 (both doses)
Number of subjects: 61
Study: 21156071

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 21159707

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) confirmed in patients with VTE
Number of subjects: 840

Group type: COMPARATOR
Intervention: Control group (no OSA)
Number of subjects: 840
Study: 21159788

Group type: EXPERIMENTAL
Intervention: Maternal dietary vitamin E intake
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood α-CEHC and γ-CEHC concentrations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maternal α-tocopherol:total lipids ratios
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metabolite:tocopherol ratios in cord blood
Number of subjects: 19
Study: 21159841

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 200
Study: 21160068

Group type: EXPERIMENTAL
Intervention: High Dicer expression in symptomatic myeloma patients
Number of subjects: 151

Group type: COMPARATOR
Intervention: Monoclonal gammopathy of undetermined significance
Number of subjects: 151
Study: 21163497

Group type: EXPERIMENTAL
Intervention: Single patch repair
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Double patch repair
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single atrial septal defect patch with primary ventricular septal defect closure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 120
Study: 21163927

Group type: EXPERIMENTAL
Intervention: G-CSF (lenograstim, 263 μg)
Number of subjects: 168
Study: 21164752

Group type: EXPERIMENTAL
Intervention: Adaptive complex diffusion despeckling filter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic data
Number of subjects: 0
Study: 21167034

Group type: EXPERIMENTAL
Intervention: Enhanced feedback group (receives performance feedback reports and a theory-informed worksheet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple feedback group (receives performance feedback reports every six months for two years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced feedback group
Number of subjects: 0
Study: 21167116

Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (15μg of hemagglutinin of each virus strain)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine
Number of subjects: 142
Study: 21168023

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3075

Group type: COMPARATOR
Intervention: Registry patients undergoing CABG
Number of subjects: 3075
Study: 21168813

Group type: EXPERIMENTAL
Intervention: Graft insertion with the EndoGlide
Number of subjects: 25
Study: 21168818

Group type: EXPERIMENTAL
Intervention: CYP1B1 mutations
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CYP1B1 and MYOC mutations
Number of subjects: 34
Study: 21169806

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 167
Study: 21169856

Group type: EXPERIMENTAL
Intervention: Febuxostat (40, 80, or 120 mg daily for up to 5 years)
Number of subjects: 116
Study: 21170669

Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg PO daily in combination with gemcitabine (1000 mg/m(2))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gemcitabine alone (implied control)
Number of subjects: 34
Study: 21170901

Group type: EXPERIMENTAL
Intervention: Offering colorectal cancer screening (CRCS) at the time of mammography without a physician's referral.
Number of subjects: 611
Study: 21170955

Group type: EXPERIMENTAL
Intervention: Melancholic MDD participants
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonmelancholic MDD participants
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 29
Study: 21172791

Group type: COMPARATOR
Intervention: 400/100 mg lopinavir/ritonavir twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 200/150 mg lopinavir/ritonavir twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 200/50 mg lopinavir/ritonavir twice daily
Number of subjects: 22
Study: 21173002

Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 1869

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1869
Study: 21173095

Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 80 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 160 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab 320 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous veltuzumab (all doses combined)
Number of subjects: 17
Study: 21173101

Group type: EXPERIMENTAL
Intervention: FBS0701, a novel oral iron chelator, given daily for 7 days at doses up to 32 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FBS0701, a novel oral iron chelator
Number of subjects: 16
Study: 21173499

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 7090

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 7090
Study: 21173649

Group type: EXPERIMENTAL
Intervention: Participants not meeting American Cancer Society guidelines for physical activity (150 min/wk)
Number of subjects: 120
Study: 21173653

Group type: EXPERIMENTAL
Intervention: Homozygous minor allele at TNF-α -308
Number of subjects: 834

Group type: COMPARATOR
Intervention: Heterozygous or homozygous major allele at TNF-α -308
Number of subjects: 834

Group type: COMPARATOR
Intervention: IL-6 -174 and IL-1β +3954 SNP
Number of subjects: 834
Study: 21173699

Group type: EXPERIMENTAL
Intervention: Mucin balls presence (single episode)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mucin balls presence (repeated episodes)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Repeated presence of mucin balls
Number of subjects: 205
Study: 21174485

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 976
Study: 21174506

Group type: EXPERIMENTAL
Intervention: Varespladib methyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care with atorvastatin 80 mg
Number of subjects: 0
Study: 21176217

Group type: COMPARATOR
Intervention: AUD patients
Number of subjects: 40
Study: 21176218

Group type: EXPERIMENTAL
Intervention: 15-20 ml/kg of 4°C cold normal saline (TH group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no pre-hospital cooling)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TH group with 17 ml/kg of cold saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TH group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TH group with in-hospital continuation of cooling
Number of subjects: 40
Study: 21176752

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg administered after HD during a 48 h - 48 h - 72 h dialysis week.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg administered before a CAPD dwell time over a 48 h - 48 h - 48 h dialysis week.
Number of subjects: 16
Study: 21177735

Group type: COMPARATOR
Intervention: Breastfeeding associated transmission in mothers who tested HIV positive at baseline (n=2870)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Breastfeeding associated transmission in mothers who seroconverted postnatally (n=334)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Breastfeeding associated transmission in mothers who seroconverted postnatally with known timing of infection (n=51)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Median plasma HIV concentration in mothers who seroconverted postnatally
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Breast milk HIV load in mothers who seroconverted postnatally
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Infants of women whose plasma sample tested negative for HIV with ELISA but positive with PCR (n=17)
Number of subjects: 14110

Group type: EXPERIMENTAL
Intervention: Overall breastfeeding associated transmission in the ZVITAMBO trial
Number of subjects: 14110
Study: 21177912

Group type: EXPERIMENTAL
Intervention: 4CMenB (3 doses at baseline, 2 months, and 6 months)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (1 dose 1 month after 4CMenB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: MenACWY-CRM
Number of subjects: 54
Study: 21178246

Group type: EXPERIMENTAL
Intervention: Constant-load treadmill tests at 3.2 km/h, 10% grade.
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Cross-correlation analysis for intra-test and test-retest reproducibility.
Number of subjects: 777
Study: 21178394

Group type: EXPERIMENTAL
Intervention: Novel synthetic TB subunit vaccine
Number of subjects: 0
Study: 21178655

Group type: EXPERIMENTAL
Intervention: 1500 mg famciclovir
Number of subjects: 53
Study: 21178824

Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 229

Group type: COMPARATOR
Intervention: No acute kidney injury (non-AKI)
Number of subjects: 229
Study: 21179201

Group type: EXPERIMENTAL
Intervention: 20,000 IU/d vitamin D3 for 12 weeks
Number of subjects: 15
Study: 21179892

Group type: EXPERIMENTAL
Intervention: Nickel–nitrilotriacetic acid (Ni–NTA) affinity chromatography
Number of subjects: 11
Study: 21180274

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment after 101-200 days (n = 6)
Number of subjects: 38

Group type: COMPARATOR
Intervention: SGRQ scores
Number of subjects: 38
Study: 21183651

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1561
Study: 21184871

Group type: EXPERIMENTAL
Intervention: Anchoring flap (AF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Flared end (FE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 21185022

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mitochondrial function measured by phosphocreatine recovery (τPCr) after sub-maximal exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mitochondrial function (τPCr)
Number of subjects: 40
Study: 21186011

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 220
Study: 21187495

Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with CEA-derived HLA-A2 binding peptide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cells transfected with CEA mRNA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control protein (KLH)
Number of subjects: 16
Study: 21188121

Group type: EXPERIMENTAL
Intervention: Resveratrol/GP (80 g of grape powder per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (normal colonic mucosa and colon cancer tissue pre-exposure)
Number of subjects: 8
Study: 21190974

Group type: EXPERIMENTAL
Intervention: High risk for thyroid disease
Number of subjects: 4394

Group type: COMPARATOR
Intervention: Low risk for thyroid disease
Number of subjects: 4394

Group type: EXPERIMENTAL
Intervention: Women with PPT
Number of subjects: 4394
Study: 21191140

Group type: COMPARATOR
Intervention: Highest quintile of fish consumption (>3.0 servings of fish/wk)
Number of subjects: 34670

Group type: COMPARATOR
Intervention: ≥3 servings of lean fish/wk
Number of subjects: 34670
Study: 21191530

Group type: EXPERIMENTAL
Intervention: Injectable risperidone long-acting therapy (25-50mg, injected every 2 weeks)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Oral aripiprazole (5-30mg/day)
Number of subjects: 355
Study: 21193540

Group type: EXPERIMENTAL
Intervention: Room light exposure before bedtime
Number of subjects: 116

Group type: COMPARATOR
Intervention: Dim light exposure before bedtime
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Room light exposure during usual hours of sleep
Number of subjects: 116
Study: 21193691

Group type: EXPERIMENTAL
Intervention: I-123 metaiodobenzylguanidine imaging with late H/M ratio <1.6 in diabetic subjects
Number of subjects: 961

Group type: COMPARATOR
Intervention: I-123 metaiodobenzylguanidine imaging with late H/M ratio ≥1.6 in diabetic subjects
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: I-123 metaiodobenzylguanidine imaging parameters
Number of subjects: 961
Study: 21194015

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT) administered at all time points
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 83
Study: 21194419

Group type: EXPERIMENTAL
Intervention: Potassium control-target of 4.0 mmol/L
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Potassium control-target of 4.5 mmol/L
Number of subjects: 1200
Study: 21195036

Group type: EXPERIMENTAL
Intervention: Desaturators (SpO(2)<90% for ≥30% recording time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-desaturators (SpO(2)≥90%)
Number of subjects: 60
Study: 21195518

Group type: EXPERIMENTAL
Intervention: Early renal service involvement (EARLI), defined as a 1-time nephrology consultation within 18 hours of the onset of AKI.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: EARLI intervention group.
Number of subjects: 176
Study: 21196729

Group type: EXPERIMENTAL
Intervention: Enlarged basilar artery diameters (BADs) in FD patients
Number of subjects: 71
Study: 21198359

Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention
Number of subjects: 51
Study: 21199970

Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Restricted transfusion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (full-term healthy children)
Number of subjects: 44
Study: 21200021

Group type: EXPERIMENTAL
Intervention: Interferon α (IFNα) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV infection of the thymus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MHC-I up-regulation
Number of subjects: 0
Study: 21203546

Group type: EXPERIMENTAL
Intervention: Ad5-HIV vaccination
Number of subjects: 100
Study: 21203574

Group type: EXPERIMENTAL
Intervention: Health facility deliveries
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Non-facility deliveries at home
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Skilled attendants
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Drying the baby
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Wrapping the baby
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Preparations for delivery
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Cord cutting practices
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Dipping in cold water
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Bathing within 6 hours
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Putting something on the cord
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Skin-to-skin contact
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Breastfeeding within 24 hours
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Breastfeeding within 1 hour
Number of subjects: 22243

Group type: COMPARATOR
Intervention: Exclusive breastfeeding in the first 3 days
Number of subjects: 22243
Study: 21204803

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 134

Group type: COMPARATOR
Intervention: No Colonoscopy
Number of subjects: 134
Study: 21205021

Group type: EXPERIMENTAL
Intervention: Insulin stimulation in type 1 diabetic patients
Number of subjects: 8
Study: 21205057

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin for 24 weeks (genotype non-1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin for 48 weeks (genotype 1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a and weight-based ribavirin
Number of subjects: 53
Study: 21205715

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21206909

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg p.o. twice daily continuously
Number of subjects: 36
Study: 21207052

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Smokers with anterior uveitis
Number of subjects: 350
Study: 21207237

Group type: EXPERIMENTAL
Intervention: Follow-up after 4 years
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline HADS score
Number of subjects: 50
Study: 21208151

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl orally disintegrating tablet (ODT)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl ODT
Number of subjects: 139
Study: 21208408

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: BNP at 24 h
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: BNP at 48 h
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: BNP at discharge
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NT-proBNP pre-discharge
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: BNP and NT-proBNP
Number of subjects: 171
Study: 21208579

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 395
Study: 21209029

Group type: EXPERIMENTAL
Intervention: GnRH deficiency
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Neuroendocrine studies
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Genetic variants
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: KAL1 variants
Number of subjects: 248
Study: 21209881

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo pioglitazone treatment
Number of subjects: 0
Study: 21210835

Group type: EXPERIMENTAL
Intervention: RVED area in males
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: RVED area for men
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: RVED area for women
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: RVED area indexed to BSA for men
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: RVED area indexed to BSA for women
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: RVED area
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Lung capacity measured as FVC
Number of subjects: 2088
Study: 21211990

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20) therapy
Number of subjects: 25
Study: 21212386

Group type: EXPERIMENTAL
Intervention: Genetic variant rs1436109 (NCAM1)
Number of subjects: 3563

Group type: EXPERIMENTAL
Intervention: Combined analysis across all stages
Number of subjects: 3563
Study: 21212770

Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 30 kg/m2 in white women
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 32.9 kg/m2 in AA women
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 29.1 kg/m2 in white men
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 30.4 kg/m2 in AA men
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 91.9 cm in white women
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 96.8 cm in AA women
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 99.4 cm in white men
Number of subjects: 6436

Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 99.1 cm in AA men
Number of subjects: 6436
Study: 21213475

Group type: EXPERIMENTAL
Intervention: 24-day regimen of drospirenone and ethinyl estradiol
Number of subjects: 52218

Group type: COMPARATOR
Intervention: 21-day regimens of other progestogens
Number of subjects: 52218

Group type: EXPERIMENTAL
Intervention: 24-day regimen of drospirenone
Number of subjects: 52218

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 52218
Study: 21216311

Group type: EXPERIMENTAL
Intervention: MVA-HIV (high dose 10^9 pfu/2 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: FPV-HIV (heterologous boost)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Homologous boosting regimen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Heterologous vector boost
Number of subjects: 150